380 related articles for article (PubMed ID: 30765520)
1. Five computational developability guidelines for therapeutic antibody profiling.
Raybould MIJ; Marks C; Krawczyk K; Taddese B; Nowak J; Lewis AP; Bujotzek A; Shi J; Deane CM
Proc Natl Acad Sci U S A; 2019 Mar; 116(10):4025-4030. PubMed ID: 30765520
[TBL] [Abstract][Full Text] [Related]
2. The Therapeutic Antibody Profiler for Computational Developability Assessment.
Raybould MIJ; Deane CM
Methods Mol Biol; 2022; 2313():115-125. PubMed ID: 34478133
[TBL] [Abstract][Full Text] [Related]
3. Drug-like antibodies with high affinity, diversity and developability directly from next-generation antibody libraries.
Azevedo Reis Teixeira A; Erasmus MF; D'Angelo S; Naranjo L; Ferrara F; Leal-Lopes C; Durrant O; Galmiche C; Morelli A; Scott-Tucker A; Bradbury ARM
MAbs; 2021; 13(1):1980942. PubMed ID: 34850665
[TBL] [Abstract][Full Text] [Related]
4. Separating clinical antibodies from repertoire antibodies, a path to in silico developability assessment.
Negron C; Fang J; McPherson MJ; Stine WB; McCluskey AJ
MAbs; 2022; 14(1):2080628. PubMed ID: 35771588
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in silico assessment of the developability of a designed monoclonal antibody library.
Wolf Pérez AM; Sormanni P; Andersen JS; Sakhnini LI; Rodriguez-Leon I; Bjelke JR; Gajhede AJ; De Maria L; Otzen DE; Vendruscolo M; Lorenzen N
MAbs; 2019; 11(2):388-400. PubMed ID: 30523762
[TBL] [Abstract][Full Text] [Related]
6. Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics.
Khetan R; Curtis R; Deane CM; Hadsund JT; Kar U; Krawczyk K; Kuroda D; Robinson SA; Sormanni P; Tsumoto K; Warwicker J; Martin ACR
MAbs; 2022; 14(1):2020082. PubMed ID: 35104168
[TBL] [Abstract][Full Text] [Related]
7. Modeling the impact of amino acid substitution in a monoclonal antibody on cation exchange chromatography.
Saleh D; Hess R; Ahlers-Hesse M; Beckert N; Schönberger M; Rischawy F; Wang G; Bauer J; Blech M; Kluters S; Studts J; Hubbuch J
Biotechnol Bioeng; 2021 Aug; 118(8):2923-2933. PubMed ID: 33871060
[TBL] [Abstract][Full Text] [Related]
8. Intrinsic physicochemical profile of marketed antibody-based biotherapeutics.
Ahmed L; Gupta P; Martin KP; Scheer JM; Nixon AE; Kumar S
Proc Natl Acad Sci U S A; 2021 Sep; 118(37):. PubMed ID: 34504010
[TBL] [Abstract][Full Text] [Related]
9. Differences in human IgG1 and IgG4 S228P monoclonal antibodies viscosity and self-interactions: Experimental assessment and computational predictions of domain interactions.
Lai PK; Ghag G; Yu Y; Juan V; Fayadat-Dilman L; Trout BL
MAbs; 2021; 13(1):1991256. PubMed ID: 34747330
[TBL] [Abstract][Full Text] [Related]
10. SAbPred: a structure-based antibody prediction server.
Dunbar J; Krawczyk K; Leem J; Marks C; Nowak J; Regep C; Georges G; Kelm S; Popovic B; Deane CM
Nucleic Acids Res; 2016 Jul; 44(W1):W474-8. PubMed ID: 27131379
[TBL] [Abstract][Full Text] [Related]
11. Developability index: a rapid in silico tool for the screening of antibody aggregation propensity.
Lauer TM; Agrawal NJ; Chennamsetty N; Egodage K; Helk B; Trout BL
J Pharm Sci; 2012 Jan; 101(1):102-15. PubMed ID: 21935950
[TBL] [Abstract][Full Text] [Related]
12. Models for Antibody Behavior in Hydrophobic Interaction Chromatography and in Self-Association.
Hebditch M; Roche A; Curtis RA; Warwicker J
J Pharm Sci; 2019 Apr; 108(4):1434-1441. PubMed ID: 30476509
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Therapeutic Antibody Developability by Combinations of In Vitro and In Silico Methods.
Wolf Pérez AM; Lorenzen N; Vendruscolo M; Sormanni P
Methods Mol Biol; 2022; 2313():57-113. PubMed ID: 34478132
[TBL] [Abstract][Full Text] [Related]
14. ABodyBuilder: Automated antibody structure prediction with data-driven accuracy estimation.
Leem J; Dunbar J; Georges G; Shi J; Deane CM
MAbs; 2016 Oct; 8(7):1259-1268. PubMed ID: 27392298
[TBL] [Abstract][Full Text] [Related]
15. Developability Assessment of Engineered Monoclonal Antibody Variants with a Complex Self-Association Behavior Using Complementary Analytical and in Silico Tools.
Shan L; Mody N; Sormani P; Rosenthal KL; Damschroder MM; Esfandiary R
Mol Pharm; 2018 Dec; 15(12):5697-5710. PubMed ID: 30395473
[TBL] [Abstract][Full Text] [Related]
16. An accelerated surface-mediated stress assay of antibody instability for developability studies.
Kopp MRG; Wolf Pérez AM; Zucca MV; Capasso Palmiero U; Friedrichsen B; Lorenzen N; Arosio P
MAbs; 2020; 12(1):1815995. PubMed ID: 32954930
[TBL] [Abstract][Full Text] [Related]
17. Homology modeling and structure-based design improve hydrophobic interaction chromatography behavior of integrin binding antibodies.
Jetha A; Thorsteinson N; Jmeian Y; Jeganathan A; Giblin P; Fransson J
MAbs; 2018; 10(6):890-900. PubMed ID: 30110240
[TBL] [Abstract][Full Text] [Related]
18. Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.
Datta-Mannan A; Thangaraju A; Leung D; Tang Y; Witcher DR; Lu J; Wroblewski VJ
MAbs; 2015; 7(3):483-93. PubMed ID: 25695748
[TBL] [Abstract][Full Text] [Related]
19. Phage display derived therapeutic antibodies have enriched aliphatic content: Insights for developability issues.
Kaleli NE; Karadag M; Kalyoncu S
Proteins; 2019 Jul; 87(7):607-618. PubMed ID: 30883916
[TBL] [Abstract][Full Text] [Related]
20. Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.
Gupta P; Horspool AM; Trivedi G; Moretti G; Datar A; Huang ZF; Chiecko J; Kenny CH; Marlow MS
J Biol Chem; 2024 Jan; 300(1):105555. PubMed ID: 38072062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
